The regulatory (neuro)peptide galanin and its three receptors (GAL1–3R) are involved in immunity and inflammation. Galanin alleviated inflammatory bowel disease (IBD) in rats. However, studies on the galanin receptors involved are lacking. We aimed to determine galanin receptor expression in IBD patients and to evaluate if GAL2R and GAL3R contribute to murine colitis. Immunohistochemical analysis revealed that granulocytes in colon specimens of IBD patients (Crohn’s disease and ulcerative colitis) expressed GAL2R and GAL3R but not GAL1R. After colitis induction with 2% dextran sulfate sodium (DSS) for 7 days, mice lacking GAL3R (GAL3R-KO) lost more body weight, exhibited more severe colonic inflammation and aggravated histologic damage, with increased infiltration of neutrophils compared to wild-type animals. Loss of GAL3R resulted in higher local and systemic inflammatory cytokine/chemokine levels. Remarkably, colitis-associated changes to the intestinal microbiota, as assessed by quantitative culture-independent techniques, were most pronounced in GAL3R-KO mice, characterized by elevated numbers of enterobacteria and bifidobacteria. In contrast, GAL2R deletion did not influence the course of colitis. In conclusion, granulocyte GAL2R and GAL3R expression is related to IBD activity in humans, and DSS-induced colitis in mice is strongly affected by GAL3R loss. Consequently, GAL3R poses a novel therapeutic target for IBD.
Neurogenic and inflammatory factors interactively contribute to the pathogenesis of inflammatory bowel diseases (IBDs) like Crohn’s disease (CD) or ulcerative colitis (UC)1,2,3,4. Consequently, neuropeptides play a key role in modulating disease activity3,4. The regulatory (neuro)peptide galanin is widely distributed in the nervous system and is expressed by non-neuronal tissues. Galanin, a 29 amino acid peptide (30 aa in humans) derived from a larger precursor peptide (ppGAL) by proteolytic cleavage, mediates its effects via three G protein-coupled receptors (GAL1–3R)5. They differ in their distribution pattern, functional coupling and signaling pathways. GAL1R and GAL3R predominantly couple to Gi/o, leading to a reduction of cAMP and inactivation of protein kinase A (PKA). GAL2R signals via multiple classes of G proteins, preferentially via Gq/11, resulting in the activation of protein kinase C (PKC)5. PKA and PKC regulate immune cell functions6,7. Importantly, we and others observed expression of galanin and galanin receptors (GALRs) in different immune cells, including neutrophils, natural killer (NK) cells, monocytes, macrophages, B and T cells8,9,10,11,12. Accordingly, galanin potently modulates neutrophil, NK cell, monocyte and macrophage functions in vitro8,9,10,11. Furthermore, GAL3R is involved in inflammatory diseases in vivo, including experimental arthritis, psoriasis and pancreatitis13,14,15.
Galanin-like immunoreactivity is found in enteric nerve bodies and fibers in all layers of the gut wall and at all levels of the gastrointestinal tract (GIT)16,17,18,19,20 with increased expression under inflammatory conditions21,22. In the gut, galanin influences the release of neurohumoral substances, gut motility, smooth muscle contractility, fluid secretion and intestinal ion flux3,23. In the colon, galanin-specific binding sites, indicating presence of GALRs, were found in the myenteric plexus24, in smooth muscle cells and nerve fibers in the submucosal layer, but also in the lamina epithelialis mucosae lining the crypts25. The density of galanin-specific binding sites in the colon remained unaffected by IBD24. In the distal and proximal rat colon comparable GAL1R and GAL2R mRNA levels but low levels of GAL3R were found26. In contrast, only GAL1R mRNA was detected in colonic cell lines and in epithelial cells of human colon27,28. Weak positive immunohistochemical (IHC) staining of GAL1R was observed in only few epithelial cells, but not in crypts. Interestingly, patients with diverse inflammatory diseases affecting the colon exhibited dramatically increased GAL1R protein expression in colonic tissue, including crypts27. Importantly, in rats with trinitrobenzenesulfonic acid (TNBS)-induced colitis, GALR agonism with galanin ameliorated the extent and severity of the colonic injury and reduced myeloperoxidase (MPO) activity, TNFα levels and nitric oxide production29,30. In contrast, in dextran sodium sulfate (DSS)-induced colitis in mice, GALR inhibition with a non-selective GALR antagonist blunted colonic inflammation22. However, GAL1R loss only affected colonic fluid secretion27,31,32,33 but not disease activity33, indicating that GAL1R might not play a central role in IBD pathophysiology. Yet, the GALR subtype mediating galanin-related effects on IBD has not been identified. Furthermore, data on protein expression of GAL2R and GAL3R in human colon were missing due to the lack of specific antibodies until recently.
Consequently, we hypothesized that colonic GALR expression might be altered during colitis and that colonic inflammation might be affected by GAL2R or GAL3R signaling. In this study we aimed to characterize GALR expression in the colon of healthy subjects and patients with CD and UC by IHC using carefully validated antibodies34. Furthermore, we investigated the role of GAL2R and GAL3R in a mouse model of colitis by analyzing histologic damage to the colon and immune activation in wild-type (WT) and receptor knockout (KO) mice.
Moreover, there is growing awareness that the interplay between commensal bacteria and the innate immune response has a pivotal role in IBD35 and influences disease susceptibility35,36. Additionally, evidence has recently emerged that neuropeptides impact the gut microbiota37. Therefore, we hypothesized that during colitis the gut microbiota might be altered in mice lacking GAL2R or GAL3R. Thus, we aimed to determine the composition of the intestinal microbiota in experimental animals following colitis induction.
Granulocytes in colon tissue of CD and UC patients express galanin receptors 2 and 3
As the galanin system is involved in inflammatory processes, we hypothesized that the expression of GALRs is altered in IBD patients. IHC analysis revealed that colonocytes, goblet cells and epithelial cells of the colonic mucosa were negative for GALR staining, independent of diagnosis (data not shown). Positive staining for GAL3R in colonic blood vessels was observed in 21 out of 24 subjects (Fig. S1), which was described previously in dermal vessels14. In the colonic mucosa of all subjects, single lymphocytes showing positive staining for all GALRs were found (data not shown). In IBD, active disease status is characterized by substantial infiltration by granulocytes into the mucosa. In our study cohort, 7 of 10 CD and 2 of 5 UC patients presented with active disease. Remarkably, weak to strong focal cytoplasmatic positivity for GAL2R and weak positivity for GAL3R but no positive staining for GAL1R was observed in mucosal granulocytes of all patients with active disease. Interestingly, only a subset of granulocytes found in inflamed human colon was positive for GAL2R (62.6% of neutrophils) or GAL3R (38.9% of neutrophils) immunoreactivity (Fig. 1; Table 1). In colon specimens of healthy individuals (Fig. 1c,f,i) or patients with inactive disease (data not shown), no or only very few granulocytes were found.
DSS-induced colitis is exacerbated in GAL3R-KO but not GAL2R-KO mice
Because we found GAL2R and GAL3R to be expressed on granulocytes in colonic mucosa of IBD patients, we studied the progression of DSS-induced colitis in mice lacking GAL2R or GAL3R. These mouse lines were on different genetic backgrounds, C57BL/6J and C57BL/6N, respectively. Therefore, the course of colitis in GAL2R-KO and GAL3R-KO mice was analyzed only in comparison to the corresponding WT group.
The first evidence of an effect of GAL2R or GAL3R loss on colitis was revealed by changes in body weight following colitis induction with DSS. Interestingly, in GAL3R-KO and corresponding WT mice, two-way ANOVA analysis of body weight data showed a significant interaction between genotype and treatment on treatment days 4 to 7 (p < 0.05; detailed F statistics are shown in Supplementary Table S5). Compared to untreated control mice, DSS treatment resulted in progressive loss of body weight that reached significance on treatment day 7 in treated GAL3R-WT mice (p = 0.025) and on days 6 (p < 0.001) and 7 (p < 0.001) in DSS-treated GAL3R-KOs. Weights of control animals did not differ between genotypes. Remarkably, GAL3R-KOs with colitis lost significantly more body weight on treatment days 5, 6 and 7 than DSS-treated WT mice (p < 0.05). At day 7, GAL3R-WT mice had lost 4.3% of their starting body weight, whereas GAL3R-KOs had lost 11.3% (p = 0.002) (Fig. 2a). As expected, colitis induction resulted in reduced food consumption (main effect treatment, p = 0.011; Fig. 2g). Importantly, the exaggerated loss of body weight in GAL3R-KOs was not caused by a stronger reduction in food intake. DSS-treated GAL3R-WT and GAL3R-KO mice consumed less food on treatment days 5–7 compared to day 1 (p < 0.05), with no difference between genotypes. Untreated mice consumed more food on day 2, and beyond that, the food intake remained constant over the 7-days treatment period (Fig. 2c). Furthermore, as the daily and cumulative water intake was independent of genotype or treatment, we can exclude the possibility that increased consumption of DSS-containing water contributed to the greater loss of body weight in GAL3R-KOs (Fig. 2e,h).
In contrast, GAL2R-KO mice exhibited a similar reduction in body weight compared to GAL2R-WT mice in response to DSS over the 7-days treatment period (treatment main effect, p = 0.027). Compared to baseline, DSS-treated GAL2R-KO and GAL2R-WT mice weighed less on treatment day 7 (p = 0.030), while control mice gained weight which reached significance on days 2 (p = 0.048) and 5 (p = 0.009), independent of genotype (Fig. 2b). Daily food and water intake remained constant in untreated mice, with no difference between genotypes (Fig. 2d,f). GAL2R-KO and GAL2R-WT mice with colitis consumed less food on days 6 (p = 0.005) and 7 (p = 0.003) compared to day 1, independent of genotype (Fig. 2d). The cumulative food intake showed only a trend toward being reduced in DSS-treated mice compared to controls (main effect treatment, p = 0.054) (Fig. 2g). Daily water intake was reduced in DSS-treated mice on treatment days 5 (p = 0.029) and 6 (p = 0.011) compared to day 1, independent of GAL2R genotype (Fig. 2f). The cumulative water intake was unaffected by GAL2R genotype or treatment (Fig. 2h).
Histologic damage and immune cell infiltration in DSS-induced colitis are exaggerated in GAL3R-KO mice
The increased loss of body weight in GAL3R-KO mice in response to DSS treatment indicated that colitis might develop more severely if GAL3R is lacking. Consequently, we analyzed disease-related variables, histologic and molecular parameters in colonic tissue and circulating cytokine/chemokine levels in experimental animals on treatment day 7 to further evaluate the course of inflammation in KO and WT mice.
Intestinal inflammation was more severe in DSS-treated GAL3R-KOs compared to GAL3R-WT mice. Histologically, the distal colon of GAL3R-KOs showed a trend toward more severe inflammatory cell infiltration during colitis compared to GAL3R-WT mice (p = 0.061), with transmural inflammation occurring in some animals (Fig. 3a,c). Importantly, GAL3R-KOs had barely preserved epithelial linings with extended ulcerations to the mucosa and destroyed crypts, while 60% of DSS-treated GAL3R-WT mice presented an intact epithelium or only minor changes to the epithelium and the mucosal architecture (Fig. 3a,d). Accordingly, histologic score points for damage to the mucosa were significantly higher in DSS-treated GAL3R-KOs compared to GAL3R-WT mice (p = 0.010) (Fig. 3d). Overall, the cumulative intestinal inflammation score was higher in DSS-treated GAL3R-KOs compared to GAL3R-WT mice (p = 0.016) (Fig. 3b).
The results relating to colitis obtained in GAL2R-KO mice were different from those observed in GAL3R-KO mice. Histologic evaluation of the distal colon revealed a similar mild to moderate infiltration of immune cells into the mucosa and submucosa in GAL2R-KO and GAL2R-WT mice following DSS treatment (Fig. 3a,c). While control mice showed undamaged epithelia and no changes to the mucosal architecture, DSS-treated GAL2R-KO and GAL2R-WT mice presented with (focal) erosions of the epithelium and destroyed crypts (Fig. 3a,d). Overall, the intestinal inflammation following colitis induction was similar in GAL2R-KO and WT animals (Fig. 3b).
The disease-related parameters colon weight, colon length, colon weight to length ratio, spleen weight and disease activity score (DAS) were significantly altered by DSS treatment in all groups (p < 0.05), except that GAL3R-KO and GAL3R-WT mice showed only a trend toward increased colon weight in response to DSS (p = 0.069). However, there were no significant differences in the disease-related parameters between DSS-treated GAL3R-KO and GAL3R-WT or between DSS-treated GAL2R-KO and GAL2R-WT mice (Fig. S2).
Colonic MPO content and number of infiltrating neutrophils in DSS-induced colitis are higher in GAL3R-KO mice
As semiquantitative scores indicated that accumulation of inflammatory cells in the colon tissue appeared to be increased in DSS-treated GAL3R-KO mice, we evaluated the amount of neutrophil-derived MPO in distal colon as an index of neutrophil influx. Colitis induction significantly elevated MPO levels in all DSS-treated groups compared to corresponding controls (p < 0.001). In agreement with the histomorphological evaluation, GAL3R-KOs had higher MPO levels compared to GAL3R-WT mice following DSS treatment (p = 0.041) (Fig. 4a). This finding is supported by an increased number of infiltrating NIMP-R14+ neutrophils in distal colon tissue of all DSS-treated mice compared to corresponding controls (p < 0.001). In addition, significantly more NIMP-R14+ neutrophils invaded the colon tissue of GAL3R-KOs compared to GAL3R-WT mice (p = 0.025) (Fig. 4b,c). In contrast, DSS-treated GAL2R-KO and GAL2R-WT animals exhibited a similar increase in MPO content and numbers of infiltrated neutrophils in the colon (Fig. 4a,b).
Colonic and systemic levels of inflammatory cytokines and chemokines are modulated by GAL3R deletion
The aggravated intestinal inflammation in GAL3R-KO animals might be caused by altered cytokine/chemokine expression. Therefore, we analyzed pro- and anti-inflammatory cytokine and chemokine mRNA levels in colon tissue and protein levels in plasma.
Induction of colitis significantly elevated the mRNA and protein expression of the majority of analyzed cytokines and chemokines in all DSS-treated groups compared to corresponding control groups (p < 0.05) (Figs. 5, 6, S3). In agreement with the increase in MPO levels and numbers of infiltrating neutrophils, transcript levels of the neutrophil-attracting chemokines CXCL1 and CCL2 were up to 5.4-fold higher in DSS-treated GAL3R-KOs compared to GAL3R-WT mice (CXCL1, p = 0.003; CCL2, p = 0.038) (Figs. 5a,c). Consistent with mRNA levels, the protein levels of these chemokines were up to threefold higher in DSS-treated GAL3R-KO compared to GAL3R-WT mice (CXCL1, p = 0.049; CCL2, p = 0.003) (Fig. 5b,d). The cytokines IL-6 and IFNγ showed a trend toward higher mRNA expression in DSS-treated GAL3R-KOs compared to treated GAL3R-WT animals (IL-6, p = 0.076; IFNγ, p = 0.059) (Fig. 5e,g). In agreement, plasma concentrations of these cytokines were significantly higher in DSS-treated GAL3R-KOs compared to GAL3R-WT mice (IL-6, p = 0.011; IFNγ, p = 0.004) (Fig. 5f,h). IFNγ concentration was 21-fold higher in DSS-treated GAL3R-KOs compared to treated GAL3R-WT animals (Fig. 5h). TNFα mRNA also showed a trend toward higher mRNA expression in DSS-treated GAL3R-KOs compared to treated GAL3R-WT animals (p = 0.070), but TNFα was not detected in plasma of GAL3R-KO and GAL3R-WT animals (Fig. 5i,j). In addition, mRNA expression of the predominantly pro-inflammatory cytokines IL-1β, IL-17A and IL-22 was up to 11.3-fold higher in DSS-treated GAL3R-KO compared to GAL3R-WT mice (IL-1β, p = 0.017; IL-17A, p = 0.005; IL-22, p = 0.019) (Fig. 6). Interestingly, upon colitis induction, IL-5 mRNA was significantly reduced only in DSS-treated GAL3R-WT mice compared to corresponding controls (p = 0.034) but was not influenced by DSS in any other group. DSS-treated GAL3R-KOs exhibited significantly higher IL-5 mRNA levels compared to GAL3R-WT mice (p = 0.009), albeit the levels were similar between healthy and treated GAL3R-KO animals (Fig. S3a). Relative mRNA expression levels of IL-10, IL-23 and TGFβ were not affected by DSS in any treated group (Fig. S3b-d). Transcript and protein levels of all analyzed cytokines and chemokines were unaffected by GAL2R loss independent of treatment (Figs. 5, 6, S3).
The intestinal microbiota in DSS-induced colitis is influenced by GAL3R deletion
The overall composition of the gut microbiota of healthy mice remained unaffected by loss of GAL2R and GAL3R (Fig. 7), which indicates that strain-specific susceptibility to DSS-induced colitis is independent of the microbiota.
Colitis induction resulted in enterobacterial enrichment in the cecal contents of all treated groups, independent of genotype (p < 0.05). Importantly, in DSS-treated GAL3R-KOs, enterobacterial copy numbers were 31.8-fold higher compared to DSS-treated GAL3R-WT animals (p = 0.009) (Fig. 7a). Remarkably, although copy numbers of bifidobacteria were similar in the cecal contents of DSS-treated mice compared to corresponding healthy controls (p < 0.05), gene numbers of bifidobacteria were 460.3-fold higher in DSS-treated GAL3R-KOs compared to DSS-treated GAL3R-WT mice (p = 0.001) (Fig. 7b). Following colitis induction copy numbers of lactobacilli were decreased and numbers of Bacteroides/Prevotella spp. were increased in GAL3R-KO and GAL3R-WT mice (p < 0.05), with no differences between genotypes (Fig. 7c,d). Other bacterial taxa as well as the total eubacterial load remained unaffected by treatment or genotype in GAL3R-KO and GAL3R-WT mice (Fig. 7e–i).
Following colitis induction, GAL2R-KO and GAL2R-WT mice exhibited similar changes to the gut microbiome as observed in GAL3R-KO and GAL3R-WT mice; however, gene numbers were similar between DSS-treated GAL2R-KO and GAL2R-WT mice (Fig. 7). In addition, DSS treatment altered the copy numbers of members of the Clostridium coccoides and Clostridium leptum group, the Mouse Intestinal Bacteroides, and the total eubacterial load in GAL2R-KOs and GAL2R-WT mice, independent of genotype (Fig. 7e,f,h,i). However, these differences in copy numbers between untreated and treated groups were smaller than one order of magnitude, and because of inter-assay variations these changes lack biological relevance.
Expression profiles of the galanin system are not affected by GAL2R or GAL3R deletion
Since our findings could be influenced by compensatory regulation of other members of the galanin system in KO animals, we analyzed mRNA expression levels of galanin and GALRs in colon tissue of experimental animals. Loss of GAL2R or GAL3R did not change the expression of the galanin system, independent of treatment (Fig. S4). Galanin mRNA levels remained unaffected by DSS, independent of genotype (Fig. S4a). In all healthy WT mice, we measured similar levels of GAL1R and GAL2R mRNA, whereas GAL3R mRNA expression was low (Fig. S4b–d). Colitis induction resulted in significant downregulation of GAL1R mRNA in GAL3R-KO and GAL3R-WT mice (main treatment effect, p = 0.048), but not in GAL2R-KO and GAL2R-WT mice (Fig. S4b). Expression levels of GAL2R and GAL3R were not affected by DSS (Fig. S4c and d).
In this study, we found expression of GAL2R and GAL3R, but not GAL1R, on granulocytes in the colon of IBD patients. Remarkably, the presence of GAL2R and GAL3R was associated with higher disease activity. In a murine colitis model, we observed exacerbated histological damage, amplified inflammatory response and considerable alterations of the gut microbiome if GAL3R, but not GAL2R, was lacking.
In the literature, involvement of the galanin system in immunity and inflammation is well established. Some studies also indicated a role in colitis22,27,29,30. However, to date, data on protein expression of GAL2R or GAL3R in the colon are missing and the GALR subtype(s) mediating galanin’s effects on colitis remain(s) to be elucidated. As galanin expression is increased in the inflamed GIT21,22, we would have expected alterations in the colonic expression of GALRs during colitis. However, in the present study IHC analysis revealed no GALR protein expression by the colonic mucosa, neither in healthy individuals, nor in IBD patients. In contrast to our findings, strongly increased GAL1R expression under inflammatory conditions has previously been reported in human colonic cell lines and in human and mouse colon tissue27,31. However, another study found no difference in the density of galanin-specific binding sites in colon tissue of healthy individuals and IBD patients24. Interestingly, we observed protein expression of GAL2R and GAL3R, but not GAL1R, on granulocytes in colonic mucosa of IBD patients. This could explain why lack of GAL1R had no influence on murine colitis33. Although only a subset of granulocytes in the colon of IBD patients expressed GAL2R or GAL3R, these cells could potentially participate in IBD-related inflammatory processes by influencing other neighboring immune cells. However, it is not clear which granulocytes express GALRs, as this specific subgroup needs to be defined by the co-expression of other markers. In agreement, we found only a subset of macrophages expresses GAL1R and GAL2R in a xanthelasma of the skin10, a small proportion of granulocytes in human glioma and pituitary adenoma expresses GAL2R, and subpopulations of glioma-associated macrophages/microglia express GAL1R, GAL2R and GAL3R, with GAL3R being the most abundant GALR subtype in tumor-infiltrating immune cells38. These findings indicate that GAL2R and/or GAL3R signaling on granulocytes in the colonic mucosa could contribute to IBD progression.
Indeed, the results of the present study partially confirm this hypothesis as we found that histologic damage and immune activation associated with DSS-induced colitis are exaggerated in GAL3R-KO, but not in GAL2R-KO mice. Due to dissimilar genetic backgrounds of the GALR-KO mouse strains, we cannot exclude that the results might be different if the strains were on the same background; however, since only a few disease-related parameters were just marginally different between GAL2R-WT (C57BL/6J) and GAL3R-WT (C57BL/6N) mice (data not shown), there is no reason to suspect this.
Loss of GAL3R aggravates colonic inflammation following DSS treatment, however, it does not influence disease-related parameters including colon weight, colon length or disease activity score. Nevertheless, this indicates that activation of GAL3R signaling could improve disease outcome. Support for this is given by a study showing beneficial effects of galanin treatment on TNBS-induced colitis in rats. Interestingly, galanin was more effective in acute compared to chronic colitis29,30. In contrast, blocking GALR signaling with the non-selective GALR antagonist M35 in mice did not affect the body weight loss in DSS-induced colitis but, compared to vehicle-treated mice, caused a more rapid recovery of the body weight after discontinuation of DSS treatment22. However, it is unclear if M35 targets GAL3R at all39. Possible explanations for the discrepant effects of pharmacological activation and blocking of GALRs are the use of different animal species, as well as different colitis models. The TNBS-induced colitis model is preferentially used to study the pathophysiology related to CD, whereas DSS-induced colitis more closely resembles UC40,41. Nevertheless, Yamaguchi et al. showed that mucosal-type mast cells (MMCs) express GAL3R mRNA at 30-fold higher levels compared to GAL2R mRNA22. Furthermore, intraperitoneal application of M35 to DSS-treated mice diminished MMC numbers in inflamed colon22. As mast cells also play an important role in animal models of colitis and in IBD in humans42,43,44, these results support the involvement of GAL3R in murine experimental colitis.
In agreement with its putative role in IBD, we reported anti-inflammatory effects of GAL3R signaling on neutrophil-related MPO levels in murine arthritis13. In contrast, pro-inflammatory properties of GAL3R signaling were observed in murine psoriasis14 and pancreatitis15. Although such biphasic effects are well known for regulatory peptide systems, it is still unclear how such functions are exerted. Accumulating data indicate that the microenvironment as well as the activation state of immune cells influences the mode of action of regulatory peptides and their receptors. For example, we observed that galanin treatment enhanced IL-12/18-stimulated IFNγ secretion by NK cells when they were seeded at a high confluency. When the confluency was low, exogenous galanin reduced the amount of IFNγ secreted9. Furthermore, galanin treatment can increase or decrease cytokine/chemokine expression levels of macrophages depending on their differentiation and polarization status10. Consequently, it is not surprising that GAL3R signaling can have pro- and anti-inflammatory effects in diseases which differ in their organ localization and immune cell profiles. Regarding colitis, it can be speculated that GAL3R participates in inflammatory processes taking place in the colon and/or directly influences immune cell functions. Remarkably, GAL3R deletion affected mRNA and protein levels of inflammatory cytokines and chemokines during colitis. The majority of these cytokines and chemokines were previously implicated in IBD pathology45,46,47,48. Interestingly, GAL3R knockout was able to modulate the expression of members of the type-1, type-2 and IL-1 family of cytokines, as well as expression of neutrophil-attracting chemokines. Likewise, in psoriatric skin, lack of GAL3R altered the cytokine expression profile14. As some of these cytokines and chemokines impact other immune cell types besides neutrophils (e.g. macrophages or T cells), and as these cell types are involved in IBD46, the number of these immune cells could also be altered in colon tissue of GAL3R-KO mice. However, we observed that in psoriatric skin only the numbers of neutrophils but not the numbers of macrophages or mast cells were affected by loss of the GAL3R14.
In psoriasis, we found GAL3R to be expressed by dermal blood vessels and to influence neovascularization14. Angiogenesis is also an important pathogenic factor in IBD progression49. Importantly, as we also observed GAL3R-positive staining on blood vessels in the human colon, GAL3R might also be involved in neovascularization during IBD.
Current research is concentrating on the role of the gut microbiota in IBD pathophysiology. It has become apparent that the intestinal microbiota not only influences disease susceptibility35,36, but also affects inflammatory processes in general50,51. Several studies have shown direct involvement of neuropeptide systems in maintaining microbiome homeostasis52,53. The composition of commensal bacteria was unaffected by loss of GAL3R in healthy mice; therefore, increased disease susceptibility due to alterations to the microbiota in GAL3R-KO mice could be excluded. Colitis induction with DSS resulted in increased abundances of enterobacteria and Bacteroides/Prevotella spp. and reductions of lactobacilli in the cecum. These changes are frequently seen in inflammatory conditions affecting the GIT54,55. Surprisingly, in DSS-treated GAL3R-KO mice, enterobacterial enrichment was more pronounced and the copy numbers of bifidobacteria were elevated. It is still controversial, however, whether this altered balance of gut microbiota constituents in DSS-treated GAL3R-KOs is a cause or consequence of the intestinal inflammation35. On the one hand, the inflammatory environment in the gut seems to offer a growth advantage to Enterobacteriaceae, resulting in the enterobacterial enrichment observed in colitis. On the other hand, Enterobacteriaceae were shown to boost inflammation and to contribute to disease development56,57. In contrast, Bifidobacteriaceae have potential anti-inflammatory properties, as they alleviated experimental colitis severity58 and were reduced in the microbiome of UC patients59. The simultaneous overgrowth of potential pro- and anti-inflammatory bacterial taxa in the cecum of DSS-treated GAL3R-KOs might appear contradictory but it could be acting as a feedback loop, which is well known in inflammatory processes. In general, these data clearly support the initial hypothesis that during colitis the gut microbiota is altered in GAL3R-KO mice.
In conclusion, the present study strongly supports the involvement of GAL3R in IBD pathophysiology. In experimental colitis, histologic damage and immune activation were aggravated and changes to the microbiota more pronounced in the absence of GAL3R. Thus, this study identifies activation of GAL3R signaling as a possible target for new treatment strategies to combat IBD. Future studies are, however, hampered by the current lack of specific and selective GAL3R agonists5. Nevertheless, the need for further research to elucidate the role of GAL3R in IBD in more detail is clearly indicated.
Materials and methods
Human patients and tissue samples
The study was approved by the local ethics committee of the Land Salzburg, Austria, (415-E/2080/5-2016) and conducted in accordance with the Helsinki Declaration of 1975 (revised 2013).
The participants were recruited at the Gastroenterological Divisions of Pediatric and Internal Clinics at the University Hospital in Salzburg, Austria. Patients with chronic abdominal pain, elevated fecal calprotectin or signs and symptoms of IBD underwent diagnostic colonoscopy, where biopsy specimens were taken from the ascending colon. Pathologists evaluated crypt architecture, acute and chronic inflammation, and regeneration of the epithelium using an arbitrary score from 0 to 3. Patients with proven IBD were assigned to our study group [CD (n = 10; 20% females; mean age 20.1 ± 5.4 years) or UC (n = 5; 60% females; mean age 20.2 ± 4.2 years)]. Healthy controls (n = 9; 77% females; mean age 18.7 ± 3.9 years) were selected to the study group when they had no inflammation or alterations in crypt architecture, or other abnormalities on endoscopic and histomorphologic evaluation. The latter was verified by a pathologist. Reasons for performing an endoscopy in healthy subjects were: hematochezia (n = 1), diarrhea (n = 1), abdominal pain (n = 3), exclusion of IBD (n = 3), or constipation (n = 1). All participants signed written informed consent or informed consent was obtained from a parent and/or legal guardian if study participants were under the age of 18.
Colon biopsies were provided as formalin-fixed and paraffin-embedded (FFPE) tissue by the Institute of Pathology of the University Hospital Salzburg, Austria. Detailed information on patients is found in Supplementary Table S1.
Experimental animals and induction of colitis
All animal procedures were approved by the ethical committee at the Federal Ministry of Science and Research of the Republic of Austria (GZ 66.010/0037-II/3b/2013) and conducted according to the Directive of the European Parliament and of the Council of 22 September 2010 (2010/63/EU). This study additionally adheres to standards articulated in the ARRIVE guidelines60.
In vivo experiments were conducted at the Medical University of Graz, Austria using 8–12-week old male GAL2R-KO (C57BL/6J background)61, GAL3R-KO (C57BL/6N background)62 and corresponding WT mice. Detailed information on animals and genotyping can be found in Supplementary Methods.
Mice were housed in groups of 2 or 3 animals per cage (one mouse in the GAL2R-KO/DSS group had to be single-housed due to aggressiveness) under controlled conditions (temperature 21 °C, humidity 50%) at a 12 h light/dark cycle (lights on/off at 0600/1800 h) in open-ventilated cages with wood chip bedding and a triangular wood pulp house as enrichment.
To induce acute colitis, mice (n = 9–11 per group) were treated with 2% DSS (36–50 kDa; MP Biochemicals, Illkirch, France), added to the drinking water, for 7 days ad libitum. Control animals received plain drinking water55,63,64. Animals were fed with standard rodent chow ad libitum.
Body weight, food and water intake were assessed daily at the same time of day (0900 h). Food and water intake were measured per cage and then divided by the number of mice in each cage to determine the daily intake per animal.
Detailed information on sample collection, assessment of the DAS64,65, evaluation of intestinal inflammation66, measurement of colonic MPO content63, real-time quantitative PCR (qPCR) analysis of cytokines/chemokines in colon tissue, and measurement of plasma cytokine/chemokine levels64 is given in Supplementary Methods.
For IHC studies, human colon sections were stained with hGAL1R (GTX108207, 1:400; Genetex, Irvine, CA, USA), hGAL2R (customized: S4510-1, 1:400; PTG, Manchester, UK), and hGAL3R (GTX108163, 1:500; Genetex) as published recently34. Mouse colon sections were stained with mNIMP-R14 (ab2557, 1:100, Abcam, Cambridge, UK) as published previously14. Detailed information on the IHC protocol and quantification of IHC staining can be found in Supplementary Methods.
Molecular analysis of microbiota in cecal contents
DNA was extracted from the contents of mouse cecum as described previously53. Total DNA was then quantified by using Quant-iT PicoGreen reagent (Thermo Fisher, Dreieich, Germany) and adjusted to 1 ng/µl. Bacterial groups abundant in the intestinal microbiota were assessed by qPCR with species-, genera-, or group-specific 16S rRNA gene primers (Tib MolBiol, Berlin, Germany) as described previously53. Gene copy numbers per nanogram DNA were determined.
Statistical analysis was performed using Graph Pad Prism 8.0 (GraphPad Software Inc., San Diego, CA, USA) and SPSS 24.0 (IBM, Armonk, NY, USA). All data sets were tested for normal distribution using the Shapiro–Wilk test and for homogeneity of variances using the Levene test. Data on daily body weight, food and water intake were analyzed by two-way repeated measures (RM) ANOVA. Post hoc testing was performed with one-way RM ANOVA and Sidak’s multiple comparison test or with two-way ANOVA and Tukey’s test, as appropriate. Data consisting of one variable and two factors were analyzed by two-way ANOVA and Tukey’s test. If ANOVA assumptions were not met or if data sets were ordinal variables (semiquantitative scores), the non-parametric Kruskal–Wallis test followed by the Mann–Whitney U test was used. p values < 0.05 were regarded as statistically significant.
The raw data supporting the conclusions of this article will be made available by the corresponding author, without undue reservation, to any qualified researcher.
Margolis, K. G. & Gershon, M. D. Enteric neuronal regulation of intestinal inflammation. Trends Neurosci. 39, 614–624. https://doi.org/10.1016/j.tins.2016.06.007 (2016).
Brinkman, D. J., Ten Hove, A. S., Vervoordeldonk, M. J., Luyer, M. D. & de Jonge, W. J. Neuroimmune interactions in the gut and their significance for intestinal immunity. Cells 8, 670. https://doi.org/10.3390/cells8070670 (2019).
Gross, K. J. & Pothoulakis, C. Role of neuropeptides in inflammatory bowel disease. Inflamm. Bowel Dis. 13, 918–932. https://doi.org/10.1002/ibd.20129 (2007).
Margolis, K. G. & Gershon, M. D. Neuropeptides and inflammatory bowel disease. Curr. Opin. Gastroenterol. 25, 503–511. https://doi.org/10.1097/MOG.0b013e328331b69e (2009).
Lang, R. et al. Physiology, signaling, and pharmacology of galanin peptides and receptors: three decades of emerging diversity. Pharmacol. Rev. 67, 118–175. https://doi.org/10.1124/pr.112.006536 (2015).
Aronoff, D. M., Canetti, C., Serezani, C. H., Luo, M. & Peters-Golden, M. Cutting edge: macrophage inhibition by cyclic AMP (cAMP): differential roles of protein kinase A and exchange protein directly activated by cAMP-1. J. Immunol. 174, 595–599. https://doi.org/10.4049/jimmunol.174.2.595 (2005).
Isakov, N. & Altman, A. Regulation of immune system cell functions by protein kinase C. Front. Immunol. 4, 384. https://doi.org/10.3389/fimmu.2013.00384 (2013).
Locker, F. et al. Galanin modulates human and murine neutrophil activation in vitro. Acta Physiol. (Oxf.) 213, 595–602. https://doi.org/10.1111/apha.12444 (2015).
Koller, A. et al. The neuropeptide galanin modulates natural killer cell function. Neuropeptides 64, 109–115. https://doi.org/10.1016/j.npep.2016.11.002 (2017).
Koller, A. et al. Galanin is a potent modulator of cytokine and chemokine expression in human macrophages. Sci. Rep. 9, 7237. https://doi.org/10.1038/s41598-019-43704-7 (2019).
Ramspacher, A. et al. Influence of the regulatory peptide galanin on cytokine expression in human monocytes. Ann. N. Y. Acad. Sci. 1455, 185–195. https://doi.org/10.1111/nyas.14111 (2019).
Chiu, I. M. et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature 501, 52–57. https://doi.org/10.1038/nature12479 (2013).
Botz, B. et al. Lack of galanin 3 receptor aggravates murine autoimmune arthritis. J. Mol. Neurosci. 59, 260–269. https://doi.org/10.1007/s12031-016-0732-9 (2016).
Locker, F. et al. Lack of galanin receptor 3 alleviates psoriasis by altering vascularization, immune cell infiltration, and cytokine expression. J. Invest. Dermatol. 138, 199–207. https://doi.org/10.1016/j.jid.2017.08.015 (2018).
Barreto, S. G. et al. Galanin receptor 3—a potential target for acute pancreatitis therapy. Neurogastroenterol. Motil. 23, e141-151. https://doi.org/10.1111/j.1365-2982.2010.01662.x (2011).
Melander, T. et al. Distribution of galanin-like immunoreactivity in the gastro-intestinal tract of several mammalian species. Cell. Tissue Res. 239, 253–270. https://doi.org/10.1007/bf00218003 (1985).
Ekblad, E., Rokaeus, A., Hakanson, R. & Sundler, F. Galanin nerve fibers in the rat gut: distribution, origin and projections. Neuroscience 16, 355–363. https://doi.org/10.1016/0306-4522(85)90008-9 (1985).
Bauer, F. E. et al. Distribution and molecular heterogeneity of galanin in human, pig, guinea pig, and rat gastrointestinal tracts. Gastroenterology 91, 877–883. https://doi.org/10.1016/0016-5085(86)90689-x (1986).
Furness, J. B., Costa, M., Rokaeus, A., McDonald, T. J. & Brooks, B. Galanin-immunoreactive neurons in the guinea-pig small intestine: their projections and relationships to other enteric neurons. Cell. Tissue Res. 250, 607–615. https://doi.org/10.1007/bf00218954 (1987).
Wang, Y. F., Mao, Y. K., McDonald, T. J. & Daniel, E. E. Distribution of galanin-immunoreactive nerves in the canine gastrointestinal tract. Peptides 16, 237–247. https://doi.org/10.1016/0196-9781(94)00170-7 (1995).
Gonkowski, S., Burlinski, P., Skobowiat, C., Majewski, M. & Calka, J. Inflammation- and axotomy-induced changes in galanin-like immunoreactive (GAL-LI) nerve structures in the porcine descending colon. Acta Vet. Hung. 58, 91–103. https://doi.org/10.1556/AVet.58.2010.1.10 (2010).
Yamaguchi, T., Ikeda, Y., Tashiro, K., Ohkawa, Y. & Kawabata, K. The role of galanin in the differentiation of mucosal mast cells in mice. Eur. J. Immunol. 50, 110–118. https://doi.org/10.1002/eji.201848061 (2020).
Rattan, S. Role of galanin in the gut. Gastroenterology 100, 1762–1768. https://doi.org/10.1016/0016-5085(91)90682-b (1991).
Mantyh, P. W. et al. Receptors for sensory neuropeptides in human inflammatory diseases: implications for the effector role of sensory neurons. Peptides 10, 627–645. https://doi.org/10.1016/0196-9781(89)90154-x (1989).
Berger, A. et al. 125I-labeled galanin binding sites in congenital innervation defects of the distal colon. Acta Neuropathol. 105, 43–48. https://doi.org/10.1007/s00401-002-0613-x (2003).
Anselmi, L., Lakhter, A., Hirano, A. A., Tonini, M. & Sternini, C. Expression of galanin receptor messenger RNAs in different regions of the rat gastrointestinal tract. Peptides 26, 815–819. https://doi.org/10.1016/j.peptides.2004.12.011 (2005).
Benya, R. V., Matkowskyj, K. A., Danilkovich, A. & Hecht, G. Galanin causes Cl- secretion in the human colon. Potential significance of inflammation-associated NF-kappa B activation on galanin-1 receptor expression and function. Ann. N. Y. Acad. Sci. 863, 64–77. https://doi.org/10.1111/j.1749-6632.1998.tb10684.x (1998).
Benya, R. V., Marrero, J. A., Ostrovskiy, D. A., Koutsouris, A. & Hecht, G. Human colonic epithelial cells express galanin-1 receptors, which when activated cause Cl- secretion. Am. J. Physiol. 276, G64-72. https://doi.org/10.1152/ajpgi.1999.276.1.G64 (1999).
Talero, E., Sanchez-Fidalgo, S., Ramon Calvo, J. & Motilva, V. Galanin in the trinitrobenzene sulfonic acid rat model of experimental colitis. Int. Immunopharmacol. 6, 1404–1412. https://doi.org/10.1016/j.intimp.2006.04.016 (2006).
Talero, E., Sanchez-Fidalgo, S., Calvo, J. R. & Motilva, V. Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regul. Pept. 141, 96–104. https://doi.org/10.1016/j.regpep.2006.12.029 (2007).
Hecht, G. et al. Pathogenic Escherichia coli increase Cl-secretion from intestinal epithelia by upregulating galanin-1 receptor expression. J. Clin. Invest. 104, 253–262. https://doi.org/10.1172/JCI6373 (1999).
Matkowskyj, K. A. et al. Galanin-1 receptor up-regulation mediates the excess colonic fluid production caused by infection with enteric pathogens. Nat. Med. 6, 1048–1051. https://doi.org/10.1038/79563 (2000).
Matkowskyj, K. A. et al. Galanin contributes to the excess colonic fluid secretion observed in dextran sulfate sodium murine colitis. Inflamm. Bowel Dis. 10, 408–416. https://doi.org/10.1097/00054725-200407000-00012 (2004).
Brunner, S. M. et al. Validation of antibody-based tools for galanin research. Peptides 120, 170009. https://doi.org/10.1016/j.peptides.2018.08.010 (2019).
Matsuoka, K. & Kanai, T. The gut microbiota and inflammatory bowel disease. Semin. Immunopathol. 37, 47–55. https://doi.org/10.1007/s00281-014-0454-4 (2015).
Li, M., Wu, Y., Hu, Y., Zhao, L. & Zhang, C. Initial gut microbiota structure affects sensitivity to DSS-induced colitis in a mouse model. Sci. China Life Sci. 61, 762–769. https://doi.org/10.1007/s11427-017-9097-0 (2018).
Holzer, P. & Farzi, A. Neuropeptides and the microbiota-gut-brain axis. Adv. Exp. Med. Biol. 817, 195–219. https://doi.org/10.1007/978-1-4939-0897-4_9 (2014).
Falkenstetter, S. et al. Galanin system in human glioma and pituitary adenoma. Front. Endocrinol. 11, 155 (2020).
Wiesenfeld-Hallin, Z. et al. Galanin-mediated control of pain: enhanced role after nerve injury. Proc. Natl. Acad. Sci. U. S. A. 89, 3334–3337. https://doi.org/10.1073/pnas.89.8.3334 (1992).
Antoniou, E. et al. The TNBS-induced colitis animal model: An overview. Ann. Med. Surg. (Lond.) 11, 9–15. https://doi.org/10.1016/j.amsu.2016.07.019 (2016).
Eichele, D. D. & Kharbanda, K. K. Dextran sodium sulfate colitis murine model: an indispensable tool for advancing our understanding of inflammatory bowel diseases pathogenesis. World J. Gastroenterol. 23, 6016–6029. https://doi.org/10.3748/wjg.v23.i33.6016 (2017).
Iba, Y., Sugimoto, Y., Kamei, C. & Masukawa, T. Possible role of mucosal mast cells in the recovery process of colitis induced by dextran sulfate sodium in rats. Int. Immunopharmacol. 3, 485–491. https://doi.org/10.1016/S1567-5769(02)00299-0 (2003).
Kurashima, Y. et al. Extracellular ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors. Nat. Commun. 3, 1034. https://doi.org/10.1038/ncomms2023 (2012).
Crowe, S. E., Luthra, G. K. & Perdue, M. H. Mast cell mediated ion transport in intestine from patients with and without inflammatory bowel disease. Gut 41, 785–792. https://doi.org/10.1136/gut.41.6.785 (1997).
Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65–70. https://doi.org/10.1136/gut.52.1.65 (2003).
Wallace, K. L., Zheng, L. B., Kanazawa, Y. & Shih, D. Q. Immunopathology of inflammatory bowel disease. World J. Gastroenterol. 20, 6–21. https://doi.org/10.3748/wjg.v20.i1.6 (2014).
Singh, U. P. et al. Chemokine and cytokine levels in inflammatory bowel disease patients. Cytokine 77, 44–49. https://doi.org/10.1016/j.cyto.2015.10.008 (2016).
Neurath, M. F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329–342. https://doi.org/10.1038/nri3661 (2014).
Alkim, C., Alkim, H., Koksal, A. R., Boga, S. & Sen, I. Angiogenesis in inflammatory bowel disease. Int. J. Inflam. 2015, 970890. https://doi.org/10.1155/2015/970890 (2015).
Holzer, P., Hassan, A. M., Jain, P., Reichmann, F. & Farzi, A. Neuroimmune pharmacological approaches. Curr. Opin. Pharmacol. 25, 13–22. https://doi.org/10.1016/j.coph.2015.09.003 (2015).
Thaiss, C. A., Zmora, N., Levy, M. & Elinav, E. The microbiome and innate immunity. Nature 535, 65–74. https://doi.org/10.1038/nature18847 (2016).
Bains, M. et al. Vasoactive intestinal peptide deficiency is associated with altered gut microbiota communities in male and female C57BL/6 mice. Front. Microbiol. 10, 2689. https://doi.org/10.3389/fmicb.2019.02689 (2019).
Heimesaat, M. M. et al. Intestinal microbiota changes in mice lacking pituitary adenylate cyclase activating polypeptide (PACAP)—bifidobacteria make the difference. Eur. J. Microbiol. Immunol. (Bp) 7, 187–199. https://doi.org/10.1556/1886.2017.00021 (2017).
Heimesaat, M. M. et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS ONE 2, e662. https://doi.org/10.1371/journal.pone.0000662 (2007).
Okayasu, I. et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98, 694–702. https://doi.org/10.1016/0016-5085(90)90290-h (1990).
Lupp, C. et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2, 119–129. https://doi.org/10.1016/j.chom.2007.06.010 (2007).
Zeng, M. Y., Inohara, N. & Nunez, G. Mechanisms of inflammation-driven bacterial dysbiosis in the gut. Mucosal Immunol. 10, 18–26. https://doi.org/10.1038/mi.2016.75 (2017).
Zhao, L., Suolang, Y., Zhou, D., Tang, Y. & Zhang, Y. Bifidobacteria alleviate experimentally induced colitis by upregulating indoleamine 2, 3-dioxygenase expression. Microbiol. Immunol. 62, 71–79. https://doi.org/10.1111/1348-0421.12562 (2018).
Duranti, S. et al. Elucidating the gut microbiome of ulcerative colitis: bifidobacteria as novel microbial biomarkers. FEMS Microbiol. Ecol. 92, fiw191. https://doi.org/10.1093/femsec/fiw191 (2016).
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 8, e1000412. https://doi.org/10.1371/journal.pbio.1000412 (2010).
Einstein, E. B., Asaka, Y., Yeckel, M. F., Higley, M. J. & Picciotto, M. R. Galanin-induced decreases in nucleus accumbens/striatum excitatory postsynaptic potentials and morphine conditioned place preference require both galanin receptor 1 and galanin receptor 2. Eur. J. Neurosci. 37, 1541–1549. https://doi.org/10.1111/ejn.12151 (2013).
Brunner, S. M. et al. GAL3 receptor KO mice exhibit an anxiety-like phenotype. Proc. Natl. Acad. Sci. U. S. A. 111, 7138–7143. https://doi.org/10.1073/pnas.1318066111 (2014).
Reichmann, F., Painsipp, E. & Holzer, P. Environmental enrichment and gut inflammation modify stress-induced c-Fos expression in the mouse corticolimbic system. PLoS ONE 8, e54811. https://doi.org/10.1371/journal.pone.0054811 (2013).
Reichmann, F. et al. Dextran sulfate sodium-induced colitis alters stress-associated behaviour and neuropeptide gene expression in the amygdala-hippocampus network of mice. Sci. Rep. 5, 9970. https://doi.org/10.1038/srep09970 (2015).
Oliveira, L. G. et al. Positive correlation between disease activity index and matrix metalloproteinases activity in a rat model of colitis. Arq. Gastroenterol. 51, 107–112. https://doi.org/10.1590/s0004-28032014000200007 (2014).
Erben, U. et al. A guide to histomorphological evaluation of intestinal inflammation in mouse models. Int. J. Clin. Exp. Pathol. 7, 4557–4576 (2014).
The study was supported by the Austrian Research Promotion Agency (FFG, 822782/THERAPEP) and the Austrian Science Fund (FWF, P25912 and P32403). SB and MMH received grant support from the German Federal Ministries of Education and Research (BMBF) in the frame of the zoonoses research consortium PAC-Campylobacter (IP7/01KI1725D) and from the Federal Ministry for Economic Affairs and Energy following a resolution of the German National Parliament, Deutscher Bundestag (ZIM, ZF4117908 AJ8). The authors greatly acknowledge support by the EC FP7 Capacities Specific Program-funded EMMA service project, which provided B6;129S5-Galr3tm1Lex/Orl mice. The authors thank Esther Fröhlich (Research Unit of Translational Neurogastroenterology, Institute of Experimental and Clinical Pharmacology, Medical University of Graz, Graz, Austria) for assisting with sample collection. We further thank Gernot Reifenberger (Institute of Microbiology, Infectious Diseases and Immunology, Charité—University Medicine Berlin, Germany) for performing the molecular gut microbiota analyses.
The authors declare no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Brunner, S.M., Reichmann, F., Leitner, J. et al. Galanin receptor 3 attenuates inflammation and influences the gut microbiota in an experimental murine colitis model. Sci Rep 11, 564 (2021). https://doi.org/10.1038/s41598-020-79456-y
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.